Sunshine Biopharma (SBFM) Gross Margin (2018 - 2026)
Sunshine Biopharma's (SBFM) quarterly Gross Margin came in at 26.2% in Q2 2026, down 1018.0% on a YoY basis from 2.85% in Q2 2025, and down 2.85% quarter-over-quarter from 26.96% in Q1 2026.
Powered by 
Analysis
Sunshine Biopharma (SBFM) Gross Margin (2018 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has reported Gross Margin for 9 consecutive years, with 26.2% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Gross Margin fell 1018.0% year-over-year to 26.2%; the trailing twelve-month figure through Jun 2026 stood at 30.3% (down 303.0% YoY), and the FY2025 full-year result was 33.76%, up 316.0% from the prior year.
- Gross Margin fell to 26.2% in Q2 2026 per SBFM's latest filing, from 26.96% in the prior quarter.
- Across five years, Gross Margin topped out at 51.2% in Q1 2022 and bottomed at 25.33% in Q2 2024.
- Historically, Gross Margin has averaged 35.56% across 5 years, with a median of 33.71% in 2023.
- The sharpest annual moves came in 2023 and 2025: Gross Margin sank 1706 bps in 2023, then jumped 1105 bps in 2025.
- Over 5 years, Gross Margin stood at 37.85% in 2022, then retreated by 12 bps to 33.44% in 2023, then retreated by 4 bps to 32.24% in 2024, then increased by 10 bps to 35.31% in 2025, then slipped by 26 bps to 26.2% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 26.2%, 26.96%, and 35.31% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 51.98% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 38.77% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 46.52% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 42.01% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 73.60% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 4.68% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 62.35% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 50.83% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 95.97% |
| 10 | Sunshine Biopharma | 1.55 Mn | -12.20 Mn | 2.43 Mn | 26.20% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.20% |
| Mar 31, 2026 | 26.96% |
| Dec 31, 2025 | 35.31% |
| Sep 30, 2025 | 32.64% |
| Jun 30, 2025 | 36.37% |
| Mar 31, 2025 | 30.67% |
| Dec 31, 2024 | 32.24% |
| Sep 30, 2024 | 33.98% |
| Jun 30, 2024 | 25.33% |
| Mar 31, 2024 | 31.22% |
| Dec 31, 2023 | 33.44% |
| Sep 30, 2023 | 33.41% |
| Jun 30, 2023 | 35.12% |
| Mar 31, 2023 | 37.35% |
| Dec 31, 2022 | 37.85% |
| Sep 30, 2022 | 50.47% |
| Jun 30, 2022 | 50.31% |
| Mar 31, 2022 | 51.20% |
| Dec 31, 2021 | 28.00% |
| Sep 30, 2021 | 61.28% |